Strong vaccine responses during chemotherapy are associated with prolonged cancer survival

Autor: Petronella B. Ottevanger, Willem Jan Krebber, Sanne Boekestijn, Judith R. Kroep, Gemma G. Kenter, Nikki M. Loof, Roy I. Lalisang, Hannelore Denys, Sjoerd H. van der Burg, Richard B. Stead, Cornelis J. M. Melief, Thierry Velu, Winald R. Gerritsen, Marij J. P. Welters, Anna K.L. Reyners, Brent A. Blumenstein, Frédéric Goffin, Hans W. Nijman, Sonja Visscher, Leon Hooftman, Ignace Vergote, Mariette I.E. van Poelgeest, Wiebren A.A. Tjalma

Publikováno v: Science Translational Medicine, 12(535). AMER ASSOC ADVANCEMENT SCIENCE
Science Translational Medicine, 12(535):8235. American Association for the Advancement of Science
Science Translational Medicine, 12
Science Translational Medicine, 12(535):8235. AMER ASSOC ADVANCEMENT SCIENCE
Science Translational Medicine, 12, 535
Science translational medicine

Therapeutic cancer vaccines have effectively induced durable regressions of premalignant oncogenic human papilloma virus type 16 (HPV16)-induced anogenital lesions. However, the treatment of HPV16-induced cancers requires appropriate countermeasures

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f17da45bfb49d86e4f147ca74e5d6333
https://doi.org/10.1126/scitranslmed.aaz8235

Pegfilgrastim Administered in an Abbreviated Schedule, Significantly Improved Neutrophil Recovery after High-Dose Radiation-Induced Myelosuppression in Rhesus Macaques

Autor: William Jackson, Melanie Cohen, Thomas J. MacVittie, Richard B. Stead, Ann M. Farese

Publikováno v: Radiation Research. 178:403-413

Conventional daily administration of filgrastim is effective in reducing the duration of severe neutropenia and enhancing survival following lethal radiation, myelosuppressive cytotoxic therapy or myeloablation and stem cell transplantation. A sustai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fee83c6fadee66b76127a1dd43a45a0a
https://doi.org/10.1667/rr2900.1

Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers

Autor: William J. Jusko, Anne Marie Duliege, Richard B. Stead, Sukyung Woo, Wojciech Krzyzanski

Publikováno v: The Journal of Clinical Pharmacology. 48:43-52

Peptidic erythropoiesis receptor agonist is a synthetic, PEGylated peptide that can promote red blood cell production upon binding to the erythropoietin receptor. The objective of this study was to characterize the pharmacokinetics and erythropoietic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a69dc95569a79d60d9bfeba4c3cc1819
https://doi.org/10.1177/0091270007309702

Hematopoietic Recovery Following Autologous Bone Marrow Transplantation in a Nonhuman Primate: Effect of Variation in Treatment Schedule with PEG‐rHuMGDF

Autor: Lorin Roskos, Ann M. Farese, Thomas J. MacVittie, Richard B. Stead

Publikováno v: STEM CELLS. 21:79-89

Mathematical modeling of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) pharmacokinetics (PK) and pharmacodynamics (PD) suggest that variations in the PEG-rHuMGDF treatment schedule could reduce the severity and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f536d1ba253d528493471be63dee8c59
https://doi.org/10.1634/stemcells.21-1-79

Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer

Autor: Wiebren A.A. Tjalma, Frédéric Goffin, Marij J. P. Welters, Mariette Ie van Poelgeest, Thierry Velu, Cornelis Joseph Melief, Roy I. Lalisang, Ignace Vergote, Judith R. Kroep, Brent A. Blumenstein, Hans W. Nijman, Petronella B. Ottevanger, Richard B. Stead, Sjoerd H. van der Burg, Hannelore Denys, Winald R. Gerritsen, Gemma G. Kenter, An K.L. Reyners

Publikováno v: Journal of Clinical Oncology. 35:140-140

140 Background: Therapeutic vaccination with HPV type 16 synthetic long peptides (HPV16-SLP) results in T cell–mediated regression of HPV16-induced premalignant lesions but fails to install effective immunity in patients with advanced HPV16-positiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d731264a4be7a5636d565990346b2aeb
https://doi.org/10.1200/jco.2017.35.7_suppl.140